NCT07475728

Brief Summary

This is a multisite EMS study that will first conduct a sequence of pragmatic, prehospital field studies to provide preliminary feasibility, acceptability, and safety data for refinement and enhancement of a subsequent single-arm prospective trial that will provide preliminary effectiveness data, from which to build a larger randomized control trail (RCT) trial.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
495

participants targeted

Target at P75+ for all trials

Timeline
36mo left

Started Jun 2026

Typical duration for all trials

Geographic Reach
1 country

3 active sites

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress1%
Jun 2026May 2029

First Submitted

Initial submission to the registry

March 4, 2026

Completed
12 days until next milestone

First Posted

Study publicly available on registry

March 16, 2026

Completed
3 months until next milestone

Study Start

First participant enrolled

June 1, 2026

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2029

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2029

Last Updated

May 28, 2026

Status Verified

May 1, 2026

Enrollment Period

2.8 years

First QC Date

March 4, 2026

Last Update Submit

May 27, 2026

Conditions

Keywords

Emergency Medical ServicesBuprenorphineSubstance use disorder treatment

Outcome Measures

Primary Outcomes (2)

  • Primary Outcome Measure for Pragmatic Field Study

    Feasibility and acceptability will be measured by the proportion of patients who accept EMS-initiated BUP among all patients who are offered the EMS-initiated BUP clinical protocol.

    Baseline

  • Primary Outcome Measure for the Single Arm Prospective Trial

    The proportion of participants engaged in MOUD within 10 days post EMS-initiated BUP among participants who received BUP and consented to be followed

    Within 10 days after EMS encounter

Secondary Outcomes (4)

  • Engagement in Treatment (30)

    Within 30 days after EMS encounter

  • Precipitated Withdrawal

    Baseline

  • ED Visits and Hospitalizations

    Within 30 days after EMS encounter

  • Adverse Events

    Within 30 days after EMS-BUP encounter

Study Arms (1)

Participants

Individuals with opioid use disorder (OUD) who encounter Emergency Medical Services (EMS) in the prehospital setting under one of two circumstances: (1) They have experienced an overdose requiring naloxone reversal or (2) They are in acute opioid abstinence withdrawal and are offered an EMS-initiated BUP clinical protocol.

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Individuals in the prehospital setting with OUD 1) presenting with overdose requiring naloxone reversal or 2) in acute opioid abstinence withdrawal offered an EMS clinical protocol across approximately three ED-EMS systems.

You may qualify if:

  • years of age or older
  • Treated by the EMS-Initiated buprenorphine clinical protocol which includes:
  • Patients that accept EMS-Initiated BUP protocol. Patients offered the EMS-Initiated BUP protocol but declined.1
  • Willing to follow study procedures.
  • Able to speak English sufficiently to understand study procedures, and to provide verbal and electronic/written consent.

You may not qualify if:

  • Patients who lack decision making capacity
  • Patients who are in police or protective custody

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Alameda Health System

Oakland, California, 94602, United States

Location

Hennepin Healthcare

Minneapolis, Minnesota, 55415, United States

Location

Cooper University Hospital

Camden, New Jersey, 08103, United States

Location

MeSH Terms

Conditions

Opioid-Related Disorders

Condition Hierarchy (Ancestors)

Narcotic-Related DisordersSubstance-Related DisordersChemically-Induced DisordersMental Disorders

Study Officials

  • Gail D'Onofrio, MD, MS

    Yale University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Gail D'Onofrio, MD, MS

CONTACT

Gerard Carroll, MD

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 4, 2026

First Posted

March 16, 2026

Study Start

June 1, 2026

Primary Completion (Estimated)

March 1, 2029

Study Completion (Estimated)

May 1, 2029

Last Updated

May 28, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will share

In line with the National Institutes of Health Helping to End Addiction Long-term (NIH HEAL) Initiative Public Access and Data Sharing Policy, publications and underlying primary data will be made available to the public.

Time Frame
Data will be made available after 1) The primary outcome paper has been accepted for publication, or 2) the data is locked for more than 18 months, whichever comes first.
Access Criteria
De-identified scientific data generated from this study will be made available to the public in the NIDA data repository, per NIDA CTN policy and the Data Management and Sharing Plan for the study.
More information

Locations